GSK shares are down 2% in London today, after the pharmaceutical group announced the discontinuation of its development program for belrestotug, an anti-TIGIT monoclonal antibody that was being developed in partnership with iTeos Therapeutics.

It explained that the decision to discontinue the program was based on new analyses of the Phase 2 GALAXIES Lung-201 and GALAXIES H&N-202 studies, which did not meet the efficacy criteria established for further development.


Copyright (c) 2025 CercleFinance.com. All rights reserved.